Origenis

Executive Summary

Origenis is a German biotechnology company founded in 2005 that leverages a proprietary AI-driven platform to discover and develop novel small molecule drugs for diseases with high unmet medical needs. The company focuses on creating synergistic drug pipelines, with particular expertise in designing compounds that can penetrate difficult biological barriers like the blood-brain barrier and the eye film. Its technology integrates AI-based drug design with efficient wet-lab synthesis and characterization to accelerate the discovery process. Although the company has been operating for over two decades, it remains private and has not publicly disclosed its stage or funding history, suggesting a steady, low-profile approach to drug development.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new preclinical candidate for CNS or ophthalmic indication60% success
• Q4 2026Strategic partnership with a larger pharma or biotech company50% success
• H2 2026Series B or later-stage financing round70% success